Could a cheap heart drug prevent 'No-Reflow' during heart attack treatment?
NCT ID NCT07536802
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether giving the drug adenosine just before emergency angioplasty (PCI) can improve blood flow in heart attack patients. About 1,148 adults having a severe type of heart attack (STEMI) will either receive adenosine or standard care. The goal is to see if adenosine reduces the 'no-reflow' problem, where blood still doesn't flow well even after opening the blocked artery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
adenosine
What this could lead to
If it works, this could point toward a simple pre-treatment to reduce heart muscle damage during emergency angioplasty for heart attacks.
What could go wrong
This is a single-center trial, so results may not apply everywhere. Adenosine can cause temporary heart block or low blood pressure, and the benefit over standard care is unproven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYOCARDIAL INFARCTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institute of Cardiovascular Diseases
RECRUITINGKarachi, Sindh, 75510, Pakistan
-
National Institute of Cardiovascular Diseases
RECRUITINGKarachi, Sindh, 75510, Pakistan
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••